Document is current
Any future updates will be listed below
-
Authors
Whaby, Michael
Ketavarapu, Gayatri
Koide, Akiko https://orcid.org/0000-0003-1796-7077
Mazzei, Megan
Mintoo, Mubashir
Glasser, Eliezra https://orcid.org/0000-0002-1371-4980
Patel, Unnatiben
Nasarre, Cecile
Sale, Matthew J.
McCormick, Frank https://orcid.org/0000-0002-6619-7120
Koide, Shohei https://orcid.org/0000-0001-5473-4358
O’Bryan, John P. https://orcid.org/0000-0001-5386-1080
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA212608, CA138313, CA194864, CA016087, CA212608)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Veterans Affairs (BX002095)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM130457, GM132055)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 12 July 2024
Revised: 27 September 2024
Accepted: 1 October 2024
First Online: 8 October 2024
Competing interests
: JPO, AK and SK are listed as inventors on a patent application on Monobodies targeting the nucleotide-free state of RAS files by the Medical University of South Carolina and New York University (No. 62/862,924). KWT, AK, and SK are listed as inventors on a patent application on mutant RAS targeting Monobodies filed by New York University (Application No. 63/121,903). AK and SK are listed as inventors on issued and pending patents on Monobody technology filed by The University of Chicago (US Patent 9512199 B2 and related pending applications), and on a pending patent on NRAS-selective monobodies (WO2023192915A1). SK is a co-founder and holds equity in Aethon Therapeutics; is a co-founder and holds equity in Revalia Bio; was an SAB member and received consulting fees from Black Diamond Therapeutics; has received research funding from Aethon Therapeutics, Argenx BVBA, Black Diamond Therapeutics, and Puretech Health. The other authors declare no competing interests. The other authors declare no competing interests.
: This study did not use any human subjects, vertebrate animals or identifiable images from human research patients.
